Brunswig-Spickenheier B, Mukhopadhyay A K
Institute for Hormone and Fertility Research, Hamburg, Germany.
Endocrinology. 1992 Sep;131(3):1445-52. doi: 10.1210/endo.131.3.1505474.
In this study the primary objectives were to localize angiotensin-II (AII) receptors on specific ovarian cells and determine whether these receptors are regulated by LH. AII receptor analysis, carried out using membrane fractions prepared from isolated thecal, granulosa, and luteal cells from bovine ovary, revealed that [125I]AII-binding sites were present only on thecal cells. The Kd and binding capacity were determined to be 0.29 +/- 0.08 nM and 66.9 +/- 8.1 fmol/mg membrane protein (mean +/- SEM from three experiments, each with duplicate determinations), respectively. None of the peptides unrelated to AII affected the binding of [125I]AII. Unlabeled AII, saralasin, and AIII were equipotent (IC50, approximately 5 nM for all three peptides) in competing with the radioligand. However, the binding affinity for AI was less by almost 2 log units. Using AII receptor subtype-specific nonpeptide antagonists, Losartan [a selective antagonist for the type 1 AII (AT1) receptor] and PD 123319 [a selective antagonist for the type 2 AII (AT2) receptor], AII receptors on thecal cells could be classified pharmacologically as AT2-type receptors. The IC50 determined from the competitive binding inhibition experiments for the various unlabeled competing substances were 5 nM, 20 nM, 200 nM, and 200 microM with respect to AII, p-amino-phenylalanine-AII, PD123319, and Losartan, respectively. Thecal cells cultured in a serum-free medium also expressed AII receptors, which could be up-regulated by LH or 8-bromo-cAMP in a dose-dependent manner. The number of AII receptors on thecal cells nearly doubled when the cells were cultured in the presence of 100 ng/ml LH, with little change in their Kd value. This increase in the number of AII receptors was inhibitable by a protein synthesis inhibitor, cycloheximide. In summary, we have demonstrated that in the bovine ovary, AII receptors belonging to AT2 subclass are predominantly expressed on thecal cells, and these receptors can be up-regulated by LH via a cAMP-dependent mechanism. Thus, the bovine thecal cells in primary culture can potentially become a useful in vitro system to study the mechanism of regulation of AII receptor induction as well as the so far unknown function of this class of receptor.
在本研究中,主要目的是将血管紧张素 II(AII)受体定位在特定的卵巢细胞上,并确定这些受体是否受促黄体生成素(LH)调节。使用从牛卵巢分离的卵泡膜细胞、颗粒细胞和黄体细胞制备的膜组分进行 AII 受体分析,结果显示[125I]AII 结合位点仅存在于卵泡膜细胞上。解离常数(Kd)和结合容量分别测定为 0.29±0.08 nM 和 66.9±8.1 fmol/mg 膜蛋白(来自三个实验的平均值±标准误,每个实验重复测定)。与 AII 无关的肽均不影响[125I]AII 的结合。未标记的 AII、沙拉新和 AIII 在与放射性配体竞争时具有同等效力(IC50,三种肽均约为 5 nM)。然而,对 AI 的结合亲和力几乎低 2 个对数单位。使用 AII 受体亚型特异性非肽拮抗剂氯沙坦[1 型 AII(AT1)受体的选择性拮抗剂]和 PD 123319[2 型 AII(AT2)受体的选择性拮抗剂],卵泡膜细胞上的 AII 受体在药理学上可归类为 AT2 型受体。针对各种未标记竞争物质的竞争性结合抑制实验确定的 IC50 分别为:AII 为 5 nM,对氨基苯丙氨酸 - AII 为 20 nM,PD123319 为 200 nM,氯沙坦为 200 μM。在无血清培养基中培养的卵泡膜细胞也表达 AII 受体,其可被 LH 或 8 - 溴 - cAMP 以剂量依赖性方式上调。当细胞在 100 ng/ml LH 存在下培养时,卵泡膜细胞上 AII 受体的数量几乎翻倍,其 Kd 值变化不大。AII 受体数量的这种增加可被蛋白质合成抑制剂环己酰亚胺抑制。总之,我们已经证明,在牛卵巢中,属于 AT2 亚类的 AII 受体主要在卵泡膜细胞上表达,并且这些受体可通过 cAMP 依赖性机制被 LH 上调。因此,原代培养的牛卵泡膜细胞有可能成为研究 AII 受体诱导调节机制以及这类受体迄今未知功能的有用体外系统。